Trial Profile
Modulation of Vascular Endothelial Growth Factor (VEGF) Using an Engineered Zinc-Finger Transcription Factor to Treat Lower Limb Intermittent Claudication
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs EWA 401 (Primary)
- Indications Intermittent claudication
- Focus Adverse reactions
- 26 Sep 2014 New trial record